Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.43 |
| ▸ | NAMPT | P43490 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | YAP1 | P46937 | 1/20 | 0.36 |
| ▸ | TEAD4 | Q15561 | 1/20 | 0.36 |
| ▸ | TEAD2 | Q15562 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.35 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.35 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.35 |
| ▸ | NCOR2 | Q9Y618 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11611028 | 0.85 | NR1I2 (0.39) | ALDH1A1NAMPTSMN1; SMN2TSHRHSD17B10 | |
| Etofamide SCHEMBL1163863 | 0.84 | KCNH2 (0.46) | ALDH1A1SMN1; SMN2LMNANPC1MAPK1 | |
| SCHEMBL11305706 | 0.81 | ALDH1A1 (0.38) | ALDH1A1SMN1; SMN2LMNATSHRNPC1 | |
| SCHEMBL11306582 | 0.80 | ALDH1A1 (0.49) | ALDH1A1KDM4ESMN1; SMN2LMNANPC1 | |
| SCHEMBL10598723 | 0.80 | ALDH1A1 (0.43) | ALDH1A1LMNATSHRNPC1ALOX15 | |
| SCHEMBL11305774 | 0.80 | LMNA (0.45) | SMN1; SMN2LMNATSHRNPC1ALOX15 | |
| SCHEMBL10598874 | 0.79 | MEN1 (0.44) | ALDH1A1KDM4ESMN1; SMN2LMNATSHR | |
| SCHEMBL11591040 | 0.79 | LMNA (0.50) | ALDH1A1KDM4ELMNATSHRNPC1 | |
| SCHEMBL10428575 | 0.78 | TSHR (0.49) | ALDH1A1SMN1; SMN2TSHRHDAC1HDAC6 | |
| SCHEMBL11307932 | 0.78 | NPC1 (0.41) | ALDH1A1NAMPTSMN1; SMN2LMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 510 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | NEOCULI PTY LTD (AU) | 2017-10-12 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-8993117-B2 | Devices with multiple surface functionality | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2015-03-31 | — | — | US | claimed |
| US-8268352-B2 | Modified release composition for highly soluble drugs | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-18 | — | — | US | claimed |
| US-8263125-B2 | Dosage form for high dose-high solubility active ingredients that provides for immediate release and modified release of the active ingredients | TORRENT PHARMACEUTICALS LIMITED (IN) | 2012-09-11 | — | — | US | claimed |
| US-20120121661-A1 | DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2012-05-17 | — | — | US | claimed |
| US-20100226943-A1 | SURFACE TOPOGRAPHIES FOR NON-TOXIC BIOADHESION CONTROL | UNIVERSITY OF FLORIDA (US) | 2010-09-09 | — | — | US | claimed |
| EP-1954244-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | Scidose, Llc (US) | 2008-08-13 | — | — | EP | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20050142069-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer | NOVADEL PHARMA, INC. | 2005-06-30 | — | — | US | claimed |
| EP-1545458-A2 | BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER | Novadel Pharma Inc. (US) | 2005-06-29 | — | — | EP | claimed |
| WO-2004019912-A2 | BUCCAL, POLAR OR NON-POLAR SPRAY OR CAPSULE CONTAINING DRUGS FOR TREATING AN INFECTIOUS DISEASE OR CANCER | NOVADEL PHARMA INC. (US) | 2004-03-11 | — | — | WO | claimed |
| US-20030082107-A1 | Buccal, polar and non-polar spray or capsule containing drugs for treating an infectious disease or cancer | NOVADEL PHARMA INC. | 2003-05-01 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| US-6114382-A | DIAGNOSING INFLAMMATORY BOWEL DISEASE(IBD) BY DETECTING PRESENCE OF MICROSPORIDIA; AND ADMINISTERING A DRUG SUCH AS TECLOZAN TO KILL LIVING MICROSPORIDIA IN THE PATIENT'S GASTROINTESTINAL TRACT; MAKING AN ANIMAL MODEL OF IBD | MORETTI ITAGIBA G (BR) | 2000-09-05 | — | — | US | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291886-A1 | METHODS FOR TREATING PROTOZOAN INFECTIONS | DPM1, ABCB11, PIGS | ALDH1A1 840/4885NAMPT 1911/4885KDM4E 3521/4885 |
| US-20120121661-A1 | DEVICES WITH MULTIPLE SURFACE FUNCTIONALITY | PHOSPHO1, CD44, SELP | ALDH1A1 2513/4885NAMPT 2211/4885KDM4E 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.